Phreesia (PHR) Projected to Post Earnings on Monday

by · The Markets Daily

Phreesia (NYSE:PHR – Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Monday, December 8th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $119.98 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Monday, December 8, 2025 at 5:00 PM ET.

Phreesia (NYSE:PHR – Get Free Report) last posted its quarterly earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.08. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The company had revenue of $117.26 million for the quarter, compared to the consensus estimate of $116.39 million. During the same quarter in the prior year, the business posted ($0.03) EPS. The firm’s quarterly revenue was up 14.9% on a year-over-year basis. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Stock Down 1.4%

Shares of Phreesia stock opened at $20.26 on Friday. The business has a fifty day simple moving average of $22.09 and a 200 day simple moving average of $25.27. The stock has a market cap of $1.21 billion, a PE ratio of -48.24 and a beta of 0.64. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02. Phreesia has a 12 month low of $18.55 and a 12 month high of $32.76.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Truist Financial boosted their target price on Phreesia from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Friday, September 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Phreesia in a research note on Friday, October 31st. Piper Sandler boosted their price objective on shares of Phreesia from $33.00 to $34.00 and gave the company an “overweight” rating in a report on Friday, September 5th. KeyCorp lowered their target price on shares of Phreesia from $35.00 to $32.00 and set an “overweight” rating for the company in a research note on Wednesday, October 8th. Finally, Mizuho initiated coverage on shares of Phreesia in a research report on Wednesday, August 27th. They set an “outperform” rating and a $36.00 price target on the stock. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.86.

Get Our Latest Stock Report on Phreesia

Insider Transactions at Phreesia

In related news, CFO Balaji Gandhi sold 4,183 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total value of $97,380.24. Following the sale, the chief financial officer directly owned 99,125 shares of the company’s stock, valued at approximately $2,307,630. The trade was a 4.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Evan Roberts sold 3,761 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $87,556.08. Following the completion of the transaction, the insider directly owned 726,837 shares of the company’s stock, valued at approximately $16,920,765.36. The trade was a 0.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 26,174 shares of company stock valued at $603,835. 5.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Phreesia

Several institutional investors and hedge funds have recently added to or reduced their stakes in PHR. Franklin Resources Inc. boosted its stake in shares of Phreesia by 1.9% during the 3rd quarter. Franklin Resources Inc. now owns 1,553,192 shares of the company’s stock worth $36,531,000 after buying an additional 28,941 shares during the last quarter. Deerfield Management Company L.P. raised its holdings in Phreesia by 10.1% during the third quarter. Deerfield Management Company L.P. now owns 1,116,752 shares of the company’s stock worth $26,266,000 after acquiring an additional 102,175 shares in the last quarter. Millennium Management LLC boosted its position in Phreesia by 730.7% during the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock valued at $25,028,000 after purchasing an additional 936,033 shares during the last quarter. Qube Research & Technologies Ltd boosted its position in Phreesia by 87.4% during the third quarter. Qube Research & Technologies Ltd now owns 730,054 shares of the company’s stock valued at $17,171,000 after purchasing an additional 340,535 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Phreesia by 0.4% in the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after purchasing an additional 2,402 shares in the last quarter. 92.10% of the stock is owned by institutional investors.

Phreesia Company Profile

(Get Free Report)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Featured Articles